Literature DB >> 8801065

Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine.

J E Sharer1, S A Wrighton.   

Abstract

Antipyrine biotransformation has been used extensively in clinical studies as a marker for general hepatic oxidative or cytochrome P450 (P450)-mediated, metabolism. Studies have indicated that more than one P450 is involved in the formation of the three major human metabolites, 4-hydroxyantipyrine, norantipyrine, and 3-hydroxymethylantipyrine. However, the specific P450s involved have not yet been determined. We have developed a sensitive method for the measurement of antipyrine metabolites formed in the in vitro incubations and applied it to determine the P450s participating in the formation of each metabolite in human liver microsomes. The identification of these P450s was accomplished through the use of simple and multivariate regression analysis, selective chemical inhibitors, and microsomes containing cDNA-expressed enzymes. These methods implicated P450s 1A2, 3A, and 2A6 in the formation of 4-hydroxyantipyrine. The predominant form involved in 3-hydroxymethylantipyrine formation was found to be 1A2, although 2C9 and 2E1 seemed to participate to a lesser extent. All forms considered (1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A) seemed to be involved in the formation of norantipyrine, although 1A2 and 2C9 only were accepted in multivariate regression analysis. Thus, antipyrine clearance is indeed a general measure of P450 oxidative capacity, with a slight to moderate weight toward 1A2, depending on the degree of 1A2 expression. Because of the multiplicity of the enzymes involved in the formation of each metabolite, the determination of these individual metabolites would be ineffective as an indicator of the levels of specific P450 forms in human subjects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8801065

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Relationships among liver and kidney volumes, lean body mass and drug clearance.

Authors:  S Nawaratne; J E Brien; E Seeman; R Fabiny; J Zalcberg; W Cosolo; P Angus; D J Morgan
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

3.  The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.

Authors:  Yukio Ishizawa; Norio Yasui-Furukori; Takenori Takahata; Mutsuo Sasaki; Tomonori Tateishi
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Antipyrine clearance and metabolite formation in primary biliary cirrhosis.

Authors:  F Jorquera; M Almar; A Linares; J L Olcóz; L Rodrigo; J González-Gallego
Journal:  Dig Dis Sci       Date:  2001-02       Impact factor: 3.199

5.  Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Mol Pharm       Date:  2018-04-10       Impact factor: 4.939

6.  Effect of tacrine hydrochloride on hepatic drug metabolism.

Authors:  T C Danbury; M Eccles; J Ford; C J Roberts
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jan-Mar       Impact factor: 2.569

7.  The effect of velnacrine on the mixed function oxidase system.

Authors:  M J Eccles; T C Danbury; J M Ford; C J Roberts
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Apr-Jun       Impact factor: 2.569

8.  Virtual Experiments Enable Exploring and Challenging Explanatory Mechanisms of Immune-Mediated P450 Down-Regulation.

Authors:  Brenden K Petersen; Glen E P Ropella; C Anthony Hunt
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.